Compare Organon & Co. Common Stock (OGN) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs State Street PDR S&P Retail ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while State Street PDR S&P Retail ETF trades at $84.83 (market cap $374.32M). The key difference: Organon & Co. Common Stock is far larger — about 9.7× State Street PDR S&P Retail ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while State Street PDR S&P Retail ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and State Street PDR S&P Retail ETF for 45 Days on average.
| OGN | XRT | |
|---|---|---|
Market Cap | $3.62B | $374.32M |
Volume | 2,892,999 | 3,523,512 |
Sector | Health | Broad Market / Factor |
52-Week High | $13.81 | $92.35 |
52-Week Low | $5.70 | $77.28 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
XRT (SPDR S&P Retail ETF) trades at $84.33, showing minimal daily movement with a 0.21% gain. Technical indicators present a mixed picture with bearish moving averages but neutral overall signals. The ETF faces headwinds from higher interest rates and inflation impacting consumer sentiment, with recent retail sales showing volatility. XRT has underperformed the broader market year-to-date, reflecting sector-specific challenges in the retail landscape.
The retail sector outlook remains cautious amid macroeconomic pressures, though potential trade resolution benefits and holiday sales projections offer some optimism. Key risks include consumer spending sensitivity to economic conditions and competitive pressures. Analyst sentiment leans neutral with expectations of continued relative underperformance versus broader market indices into 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
